SMART TECHNOLOGY PLATFORM
COMPOUNDS IN PIPELINE
Status in the preclinical stage
Dr. Yelena Wainman manages the CytoSwitch project. She completed her PhD in medicinal chemistry at the University of Cambridge followed by a post-doc at Harvard Medical School working on photoswitchable epigenetic inhibitors. She was active in the biotech/start-up scene in both Cambridge and Boston (Kaleidoscope, Palletech, Oxbridge Biotech Roundtable).
Dr. Doris Mangelberger leads the early discovery studies at CytoSwitch. After a PhD in molecular biology at the Univ. of Salzburg, where she investigated signaling mechanisms involved in cancer formation, she did a postdoc at the Univ. of Michigan Cancer Center. There she developed skin cancer models for basic research and performed preclinical drug testing in vivo.
Dr. Oliver Thorn-Seshold is the chemist behind the compound pipeline design for CytoSwitch. He leads a junior research group at the LMU Munich, developing small molecule inhibitors as reagents and cancer therapeutics. After a PhD in fluorescent probes at the University of Lyon, he began research into turning known cancer drugs into light-sensitive analogues.
Tilmann Petersen manages the business related side of CytoSwitch. He has 10 years of experience as co-founder and manager in various Biotech and High-Tech Startups. He worked as Head of Finance in the VivoCell Biosolutions AG group, as CFO for Pioneers.io and as CEO of Nu Emotions.
CYTOSWITCH IN THE MEDIA